Literature DB >> 7742161

Protein binding of propranolol and verapamil enantiomers in maternal and foetal serum.

F M Belpaire1, P Wynant, P Van Trappen, M Dhont, A Verstraete, M G Bogaert.   

Abstract

The protein binding of the enantiomers of propranolol and verapamil was measured in 19 pairs of maternal and foetal serum obtained at delivery. The binding of the enantiomers of both drugs was lower in foetal than in maternal serum. In maternal serum the mean (+/- s.d.) unbound percentages were 22.4 +/- 6.2 and 20.7 +/- 6.6 for R- and S-propranolol, and 16.8 +/- 5.5 and 22.5 +/- 6.2 for R- and S-verapamil; in foetal serum the values were 38.8 +/- 8.6 and 40.4 +/- 10.6 for R- and S-propranolol, and 34.7 +/- 10.5 and 44.8 +/- 10.7 for R- and S-verapamil. For propranolol, in maternal, but not in foetal serum, the difference between the binding of the R- and S-enantiomers was significant; the R/S ratio was significantly (P < 0.01) larger in the mother (1.099 +/- 0.072) than in the foetus (0.973 +/- 0.068). For verapamil, the difference in binding between the R- and S-enantiomers was significant in both maternal and foetal serum, but the R/S ratio was similar in mother (0.735 +/- 0.098) and foetus (0.763 +/- 0.070). Serum alpha 1-acid glycoprotein (AAG) concentrations were markedly higher and albumin concentrations slightly lower in maternal than in foetal samples. The binding of the four enantiomers in maternal and foetal serum was correlated (P < 0.001) with the AAG concentration (r propranolol: R 0.749, S 0.746; r verapamil: R 0.753, S 0.782). Our findings show that measurement of concentrations of total, unresolved drug allow a reasonably accurate assessment of transplacental gradients of individual isomers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742161      PMCID: PMC1364960          DOI: 10.1111/j.1365-2125.1995.tb04430.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  Enantioselective aspects of drug action and disposition: therapeutic pitfalls.

Authors:  F Jamali; R Mehvar; F M Pasutto
Journal:  J Pharm Sci       Date:  1989-09       Impact factor: 3.534

Review 2.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  Stereoselective protein binding of verapamil enantiomers.

Authors:  A S Gross; B Heuer; M Eichelbaum
Journal:  Biochem Pharmacol       Date:  1988-12-15       Impact factor: 5.858

Review 4.  The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state.

Authors:  M D Hill; F P Abramson
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

5.  Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs.

Authors:  B Krauer; P Dayer; R Anner
Journal:  Br J Obstet Gynaecol       Date:  1984-09

6.  The influence of aging on the stereoselective pharmacokinetics of propranolol in the rat.

Authors:  A M Vermeulen; F M Belpaire; E Moerman; F de Smet; M G Bogaert
Journal:  Chirality       Date:  1992       Impact factor: 2.437

7.  Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant.

Authors:  M Wood; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

8.  Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin.

Authors:  U K Walle; T Walle; S A Bai; L S Olanoff
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

9.  Enantioselective inhibitory effect of nicardipine on the hepatic clearance of propranolol in man.

Authors:  I Vercruysse; F Belpaire; P Wynant; D L Massart; A G Dupont
Journal:  Chirality       Date:  1994       Impact factor: 2.437

10.  Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat.

Authors:  M E Laethem; F M Belpaire; P Wijnant; M T Rosseel; M G Bogaert
Journal:  Chirality       Date:  1994       Impact factor: 2.437

  10 in total
  5 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building.

Authors:  Khaled Abduljalil; Xian Pan; Amita Pansari; Masoud Jamei; Trevor N Johnson
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

3.  Protein binding predictions in infants.

Authors:  Patrick J McNamara; Jane Alcorn
Journal:  AAPS PharmSci       Date:  2002

4.  Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.

Authors:  André Dallmann; Ibrahim Ince; Juri Solodenko; Michaela Meyer; Stefan Willmann; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

5.  Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects.

Authors:  Anil R Maharaj; Daniel Gonzalez; Michael Cohen-Wolkowiez; Christoph P Hornik; Andrea N Edginton
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.